Last edition
News about "Gilgamesh Pharmaceuticals "
AbbVie to Acquire Gilgamesh's Psychedelic Antidepressant Bretisilocin in USD 1.2 Billion Deal
AbbVie has announced a USD 1.2 billion deal to acquire Gilgamesh Pharmaceuticals’ lead candidate bretisilocin, a next-generation psychedelic compound in clinical development for treating moderate-to-severe major depressive disorder.
Gilgamesh Pharmaceuticals | 26/08/2025 | By Mrinmoy Dey
AbbVie Partners with Gilgamesh Pharmaceuticals to Develop Therapies for Psychiatric Disorders
AbbVie has signed an option-to-license agreement with Gilgamesh Pharmaceuticals to develop next-generation therapies for psychiatric disorders.
Gilgamesh Pharmaceuticals | 14/05/2024 | By Aishwarya | 600
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy